<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37631931</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Substitution of Coxsackievirus A16 VP1 BC and EF Loop Altered the Protective Immune Responses in Chimera Enterovirus A71.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1363</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines11081363</ELocationID><Abstract><AbstractText>Hand, foot and mouth disease (HFMD) is a childhood disease caused by enterovirus A71 (EV-A71) and coxsackievirus A16 (CV-A16). Capsid loops are important epitopes for EV-A71 and CV-A16. Seven chimeric EV-A71 (ChiE71) involving VP1 BC (45.5% similarity), DE, EF, GH and HI loops, VP2 EF loop and VP3 GH loop (91.3% similarity) were substituted with corresponding CV-A16 loops. Only ChiE71-1-BC, ChiE71-1-EF, ChiE71-1-GH and ChiE71-3-GH were viable. EV-A71 and CV-A16 antiserum neutralized ChiE71-1-BC and ChiE71-1-EF. Mice immunized with inactivated ChiE71 elicited high IgG, IFN-γ, IL-2, IL-4 and IL-10. Neonatal mice receiving passive transfer of WT EV-A71, ChiE71-1-EF and ChiE71-1-BC immune sera had 100%, 80.0% and no survival, respectively, against lethal challenges with EV-A71, suggesting that the substituted CV-A16 loops disrupted EV-A71 immunogenicity. Passive transfer of CV-A16, ChiE71-1-EF and ChiE71-1-BC immune sera provided 40.0%, 20.0% and 42.9% survival, respectively, against CV-A16. One-day-old neonatal mice immunized with WT EV-A71, ChiE71-1-BC, ChiE71-1-EF and CV-A16 achieved 62.5%, 60.0%, 57.1%, and no survival, respectively, after the EV-A71 challenge. Active immunization using CV-A16 provided full protection while WT EV-A71, ChiE71-1-BC and ChiE71-1-EF immunization showed partial cross-protection in CV-A16 lethal challenge with survival rates of 50.0%, 20.0% and 40%, respectively. Disruption of a capsid loop could affect virus immunogenicity, and future vaccine design should include conservation of the enterovirus capsid loops.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Xiu Hui</ForeName><Initials>XH</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Wei Lim</ForeName><Initials>WL</Initials><Identifier Source="ORCID">0000-0002-4178-2614</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Center of Theoretical and Computational Physics, Faculty of Science, Universiti Malaya, Kuala Lumpur 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Vannajan Sanghiran</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Center of Theoretical and Computational Physics, Faculty of Science, Universiti Malaya, Kuala Lumpur 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdullah</LastName><ForeName>Syahril</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine &amp; Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comparative Medicine and Technology Unit, Institute of Bioscience, Universiti Putra Malaysia, Serdang 43400, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jasni</LastName><ForeName>Kartini</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Comparative Medicine and Technology Unit, Institute of Bioscience, Universiti Putra Malaysia, Serdang 43400, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suarni</LastName><ForeName>Saiful Qushairi</ForeName><Initials>SQ</Initials><AffiliationInfo><Affiliation>Comparative Medicine and Technology Unit, Institute of Bioscience, Universiti Putra Malaysia, Serdang 43400, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perera</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6678-8222</Identifier><AffiliationInfo><Affiliation>Institute of Health and Community Medicine, Universiti Malaysia Sarawak, Kota Samarahan 94300, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sam</LastName><ForeName>I-Ching</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Yoke Fun</ForeName><Initials>YF</Initials><Identifier Source="ORCID">0000-0001-7089-0510</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FRGS/1/2018/SKK11/UM/02/2</GrantID><Agency>Ministry of Higher Education</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">capsid loop</Keyword><Keyword MajorTopicYN="N">coxsackievirus A16</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">enterovirus A71</Keyword><Keyword MajorTopicYN="N">foot and mouth disease</Keyword><Keyword MajorTopicYN="N">hand</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37631931</ArticleId><ArticleId IdType="pmc">PMC10458053</ArticleId><ArticleId IdType="doi">10.3390/vaccines11081363</ArticleId><ArticleId IdType="pii">vaccines11081363</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiu M.L., Luo S.T., Chen Y.Y., Chung W.Y., Duong V., Dussart P., Chan Y.F., Perera D., Ooi M.H., Thao N.T.T. Establishment of Asia-Pacific network for enterovirus surveillance. J. Vaccine. 2020;38:1–9. doi: 10.1016/j.vaccine.2019.09.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.09.111</ArticleId><ArticleId IdType="pubmed">31679864</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.H.P., Chong Y.M., Tay C.G., Koh M.T., Chem Y.K., Noordin N., Jahis R., Sam I.C., Chan Y.F. Detection of enteroviruses during a 2018 hand, foot and mouth disease outbreak in Malaysia. Trop. Biomed. 2021;38:150–153. doi: 10.47665/tb.38.1.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.47665/tb.38.1.026</ArticleId><ArticleId IdType="pubmed">33797539</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan Y.F., Wee K.L., Chiam C.W., Khor C.S., Chan S.Y., Amalina W.M., Sam I.C. Comparative genetic analysis of VP4, VP1 and 3D gene regions of enterovirus 71 and coxsackievirus A16 circulating in Malaysia between 1997–2008. Trop. Biomed. 2012;29:451–466.</Citation><ArticleIdList><ArticleId IdType="pubmed">23018509</ArticleId></ArticleIdList></Reference><Reference><Citation>NikNadia N.M.N., Sam I.C., Rampal S., WanNorAmalina W.M.Z., NurAtifah G., Verasahib K., Ong C.C., MohdAdib M., Chan Y.F. Cyclical patterns of hand, foot and mouth disease caused by enterovirus A71 in Malaysia. PLoS Negl. Trop. Dis. 2016;10:e0004562. doi: 10.1371/journal.pntd.0004562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0004562</ArticleId><ArticleId IdType="pmc">PMC4806993</ArticleId><ArticleId IdType="pubmed">27010319</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi M.H., Wong S.C., Lewthwaite P., Cardosa M.J., Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097–1105. doi: 10.1016/S1474-4422(10)70209-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P., Liu Y., Ma H.-C., Paul A.V., Wimmer E. Picornavirus morphogenesis. Microbiol. Mol. Biol. Rev. 2014;78:418–437. doi: 10.1128/MMBR.00012-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.00012-14</ArticleId><ArticleId IdType="pmc">PMC4187686</ArticleId><ArticleId IdType="pubmed">25184560</ArticleId></ArticleIdList></Reference><Reference><Citation>Aw-Yong K.L., Sam I.C., Koh M.T., Chan Y.F. Immunodominant IgM and IgG epitopes recognized by antibodies induced in enterovirus A71-associated hand, foot and mouth disease patients. PLoS ONE. 2016;11:e0165659. doi: 10.1371/journal.pone.0165659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0165659</ArticleId><ArticleId IdType="pmc">PMC5091889</ArticleId><ArticleId IdType="pubmed">27806091</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor P.D., Ferguson M., Evans D.M., Almond J.W., Icenogle J.P. Antigenic structure of polioviruses of serotypes 1, 2 and 3. Pt 7J. Gen. Virol. 1986;67:1283–1291. doi: 10.1099/0022-1317-67-7-1283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-67-7-1283</ArticleId><ArticleId IdType="pubmed">2425046</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox H., Knowlson S., Minor P.D., Macadam A.J. Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines. PLoS Pathog. 2017;13:e1006117. doi: 10.1371/journal.ppat.1006117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006117</ArticleId><ArticleId IdType="pmc">PMC5245777</ArticleId><ArticleId IdType="pubmed">28103317</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahar M.W., Porta C., Fox H., Macadam A.J., Fry E.E., Stuart D.I. Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. Npj Vaccines. 2021;6:5. doi: 10.1038/s41541-020-00267-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-00267-3</ArticleId><ArticleId IdType="pmc">PMC7794334</ArticleId><ArticleId IdType="pubmed">33420068</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D.G.W., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T.K., Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125:61–68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Chou A.H., Lien S.P., Lin H.Y., Liu S.J., Chang J.Y., Guo M.S., Chow Y.H., Yang W.S., Chang K.H., et al. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine. 2011;29:4362–4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Anasir M.I., Poh C.L. Advances in antigenic peptide-based vaccine and neutralizing antibodies against viruses causing hand, foot, and mouth disease. Int. J. Mol. Sci. 2019;20:1256. doi: 10.3390/ijms20061256.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20061256</ArticleId><ArticleId IdType="pmc">PMC6471744</ArticleId><ArticleId IdType="pubmed">30871133</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdin A.D., Wimmer E. Construction of a poliovirus type 1/type 2 antigenic hybrid by manipulation of neutralization antigenic site II. J. Virol. 1989;63:5251–5257. doi: 10.1128/jvi.63.12.5251-5257.1989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.63.12.5251-5257.1989</ArticleId><ArticleId IdType="pmc">PMC251190</ArticleId><ArticleId IdType="pubmed">2479772</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.H.P., Tan C.W., Tee H.K., Ong K.C., Sam I.C., Chan Y.F. Vaccine candidates generated by codon and codon pair deoptimization of enterovirus A71 protect against lethal challenge in mice. Vaccine. 2021;39:1708–1720. doi: 10.1016/j.vaccine.2021.02.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.02.024</ArticleId><ArticleId IdType="pubmed">33640144</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee H.K., Tan C.W., Yogarajah T., Lee M.H.P., Chai H.J., Hanapi N.A., Yusof S.R., Ong K.C., Lee V.S., Sam I.C., et al. Electrostatic interactions at the five-fold axis alter heparin-binding phenotype and drive enterovirus A71 virulence in mice. PLoS Pathog. 2019;15:e1007863. doi: 10.1371/journal.ppat.1007863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007863</ArticleId><ArticleId IdType="pmc">PMC6881073</ArticleId><ArticleId IdType="pubmed">31730673</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans D.J., McKeating J., Meredith J.M., Burke K.L., Katrak K., John A., Ferguson M., Minor P.D., Weiss R.A., Almond J.W. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature. 1989;339:385–388. doi: 10.1038/339385a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/339385a0</ArticleId><ArticleId IdType="pubmed">2542797</ArticleId></ArticleIdList></Reference><Reference><Citation>Colbère-Garapin F., Christodoulou C., Crainic R., Garapin A.-C., Candrea A. Addition of a foreign oligopeptide to the major capsid protein of poliovirus. Proc. Natl. Acad. Sci. USA. 1988;85:8668–8672. doi: 10.1073/pnas.85.22.8668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.85.22.8668</ArticleId><ArticleId IdType="pmc">PMC282521</ArticleId><ArticleId IdType="pubmed">2460875</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Tee H.K., Lee M.H.P., Sam I.C., Chan Y.F. Enterovirus A71 DNA-launched infectious clone as a robust reverse genetic tool. PLoS ONE. 2016;11:e0162771. doi: 10.1371/journal.pone.0162771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0162771</ArticleId><ArticleId IdType="pmc">PMC5019408</ArticleId><ArticleId IdType="pubmed">27617744</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong K.C., Devi S., Cardosa M.J., Wong K.T. Formaldehyde-Inactivated Whole-Virus Vaccine Protects a Murine Model of Enterovirus 71 Encephalomyelitis against Disease. J. Virol. 2010;84:661–665. doi: 10.1128/JVI.00999-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00999-09</ArticleId><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.-C., Guo M.-S., Lin F.H.-Y., Hsiao K.-N., Chang K.H.-W., Chou A.-H., Wang Y.-C., Chen Y.-C., Yang C.-S., Chong P.C.-S. Purification and Characterization of Enterovirus 71 Viral Particles Produced from Vero Cells Grown in a Serum-Free Microcarrier Bioreactor System. PLoS ONE. 2011;6:e20005. doi: 10.1371/journal.pone.0020005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020005</ArticleId><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter T.S., Ren J., Tuthill T.J., Rowlands D.J., Stuart D.I., Fry E.E. A plate-based high-throughput assay for virus stability and vaccine formulation. J. Virol. Methods. 2012;185:166–170. doi: 10.1016/j.jviromet.2012.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.06.014</ArticleId><ArticleId IdType="pmc">PMC3470038</ArticleId><ArticleId IdType="pubmed">22744000</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterhouse A., Bertoni M., Bienert S., Studer G., Tauriello G., Gumienny R., Heer F.T., de Beer T.A.P., Rempfer C., Bordoli L., et al. SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46:W296–W303. doi: 10.1093/nar/gky427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky427</ArticleId><ArticleId IdType="pmc">PMC6030848</ArticleId><ArticleId IdType="pubmed">29788355</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurrus E., Engel D., Star K., Monson K., Brandi J., Felberg L.E., Brookes D.H., Wilson L., Chen J., Liles K., et al. Improvements to the APBS biomolecular solvation software suite. Protein Sci. 2018;27:112–128. doi: 10.1002/pro.3280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3280</ArticleId><ArticleId IdType="pmc">PMC5734301</ArticleId><ArticleId IdType="pubmed">28836357</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe D.R., Cheatham T.E. PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. J. Chem. Theory Comput. 2013;9:3084–3095. doi: 10.1021/ct400341p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct400341p</ArticleId><ArticleId IdType="pubmed">26583988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X., Fan C., Ku Z., Zuo T., Kong L., Zhang C., Shi J., Liu Q., Chen T., Zhang Y., et al. Structural basis for recognition of human enterovirus 71 by a bivalent broadly neutralizing monoclonal antibody. PLoS Pathog. 2016;12:e1005454. doi: 10.1371/journal.ppat.1005454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005454</ArticleId><ArticleId IdType="pmc">PMC4777393</ArticleId><ArticleId IdType="pubmed">26938634</ArticleId></ArticleIdList></Reference><Reference><Citation>He M., Xu L., Zheng Q., Zhu R., Yin Z., Zha Z., Lin Y., Yang L., Huang Y., Ye X., et al. Identification of antibodies with non-overlapping neutralization sites that target coxsackievirus A16. Cell Host Microbe. 2020;27:249–261.e245. doi: 10.1016/j.chom.2020.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.01.003</ArticleId><ArticleId IdType="pmc">PMC7539366</ArticleId><ArticleId IdType="pubmed">32027857</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zundert G.C.P., Rodrigues J., Trellet M., Schmitz C., Kastritis P.L., Karaca E., Melquiond A.S.J., van Dijk M., de Vries S.J., Bonvin A. The HADDOCK2.2 web server: User-friendly integrative modeling of biomolecular complexes. J. Mol. Biol. 2016;428:720–725. doi: 10.1016/j.jmb.2015.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2015.09.014</ArticleId><ArticleId IdType="pubmed">26410586</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries S.J., van Dijk M., Bonvin A.M. The HADDOCK web server for data-driven biomolecular docking. Nat. Protoc. 2010;5:883–897. doi: 10.1038/nprot.2010.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2010.32</ArticleId><ArticleId IdType="pubmed">20431534</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera--a visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25:1605–1612. doi: 10.1002/jcc.20084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20084</ArticleId><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y.-L., Lin T.-M., Wang S.-Y., Wang J.-R. The role of conserved arginine and proline residues in enterovirus VP1 protein. J. Microbiol. Immunol. Infect. 2022;55:590–597. doi: 10.1016/j.jmii.2022.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2022.01.004</ArticleId><ArticleId IdType="pubmed">35232679</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z., Ye X., Shi J., Wang X., Liu Q., Huang Z., López S. Single neutralizing monoclonal antibodies targeting the VP1 GH loop of enterovirus 71 inhibit both virus attachment and internalization during viral entry. J. Virol. 2015;89:12084–12095. doi: 10.1128/JVI.02189-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02189-15</ArticleId><ArticleId IdType="pmc">PMC4645313</ArticleId><ArticleId IdType="pubmed">26401034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X., Ku Z., Liu Q., Wang X., Shi J., Zhang Y., Kong L., Cong Y., Huang Z. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J. Virol. 2014;88:72–81. doi: 10.1128/JVI.01848-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01848-13</ArticleId><ArticleId IdType="pmc">PMC3911748</ArticleId><ArticleId IdType="pubmed">24131712</ArticleId></ArticleIdList></Reference><Reference><Citation>Catching A., Yeh M.T., Bianco S., Capponi S., Andino R. A tradeoff between enterovirus A71 particle stability and cell entry. bioRxiv. 2022 doi: 10.1101/2022.09.28.506941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.09.28.506941</ArticleId><ArticleId IdType="pmc">PMC10656440</ArticleId><ArticleId IdType="pubmed">37978288</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y.-L., Huang S.-W., Shen C.-Y., Cheng D., Wang J.-R. Conserved Residues Adjacent to ß-Barrel and Loop Intersection among Enterovirus VP1 Affect Viral Replication: Potential Target for Anti-Enteroviral Development. Viruses. 2022;14:364. doi: 10.3390/v14020364.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14020364</ArticleId><ArticleId IdType="pmc">PMC8877150</ArticleId><ArticleId IdType="pubmed">35215957</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingston N.J., Shegdar M., Snowden J.S., Fox H., Groppelli E., Macadam A., Rowlands D.J., Stonehouse N.J. Thermal stabilization of enterovirus A 71 and production of antigenically stabilized empty capsids. J. Gen. Virol. 2022;103:001771. doi: 10.1099/jgv.0.001771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001771</ArticleId><ArticleId IdType="pmc">PMC10019091</ArticleId><ArticleId IdType="pubmed">35997623</ArticleId></ArticleIdList></Reference><Reference><Citation>Teilum K., Olsen J.G., Kragelund B.B. Functional aspects of protein flexibility. Cell Mol. Life Sci. 2009;66:2231–2247. doi: 10.1007/s00018-009-0014-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-009-0014-6</ArticleId><ArticleId IdType="pmc">PMC11115794</ArticleId><ArticleId IdType="pubmed">19308324</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordey S., Petty T.J., Schibler M., Martinez Y., Gerlach D., van Belle S., Turin L., Zdobnov E., Kaiser L., Tapparel C. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog. 2012;8:e1002826. doi: 10.1371/journal.ppat.1002826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002826</ArticleId><ArticleId IdType="pmc">PMC3406088</ArticleId><ArticleId IdType="pubmed">22910880</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaini Z., Phuektes P., McMinn P. Mouse adaptation of a sub-genogroup B5 strain of human enterovirus 71 is associated with a novel lysine to glutamic acid substitution at position 244 in protein VP1. Virus Res. 2012;167:86–96. doi: 10.1016/j.virusres.2012.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2012.04.009</ArticleId><ArticleId IdType="pubmed">22575826</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H.H., Yang C.F., Murdin A.D., Klein M.H., Harber J.J., Kew O.M., Wimmer E. Mouse neurovirulence determinants of poliovirus type 1 strain LS-a map to the coding regions of capsid protein VP1 and proteinase 2Apro. J. Virol. 1994;68:7507–7515. doi: 10.1128/jvi.68.11.7507-7515.1994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.68.11.7507-7515.1994</ArticleId><ArticleId IdType="pmc">PMC237193</ArticleId><ArticleId IdType="pubmed">7933134</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray M.G., Bradley J., Yang X.F., Wimmer E., Moss E.G., Racaniello V.R. Poliovirus host range is determined by a short amino acid sequence in neutralization antigenic site I. Science. 1988;241:213–215. doi: 10.1126/science.2838906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2838906</ArticleId><ArticleId IdType="pmc">PMC3908517</ArticleId><ArticleId IdType="pubmed">2838906</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss E.G., Racaniello V.R. Host range determinants located on the interior of the poliovirus capsid. EMBO J. 1991;10:1067–1074. doi: 10.1002/j.1460-2075.1991.tb08046.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1991.tb08046.x</ArticleId><ArticleId IdType="pmc">PMC452759</ArticleId><ArticleId IdType="pubmed">1850692</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Huang X., Liu Q., Huang Z. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine. 2013;31:2130–2136. doi: 10.1016/j.vaccine.2013.02.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.02.051</ArticleId><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou A.H., Liu C.C., Chang J.Y., Lien S.P., Guo M.S., Tasi H.P., Hsiao K.N., Liu S.J., Sia C., Wu S.C., et al. Immunological evaluation and comparison of different EV71 vaccine candidates. Clin. Dev. Immunol. 2012;2012:831282. doi: 10.1155/2012/831282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/831282</ArticleId><ArticleId IdType="pmc">PMC3447357</ArticleId><ArticleId IdType="pubmed">23008736</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou A.H., Liu C.C., Chang J.Y., Jiang R., Hsieh Y.C., Tsao A., Wu C.L., Huang J.L., Fung C.P., Hsieh S.M., et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4a in adult volunteers. PLoS ONE. 2013;8:e79783. doi: 10.1371/journal.pone.0079783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079783</ArticleId><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Imura A., Sudaka Y., Takashino A., Tamura K., Kobayashi K., Nagata N., Nishimura H., Mizuta K., Koike S. Development of an Enterovirus 71 Vaccine Efficacy Test Using Human Scavenger Receptor B2 Transgenic Mice. J. Virol. 2020;94:e01921-19. doi: 10.1128/JVI.01921-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01921-19</ArticleId><ArticleId IdType="pmc">PMC7158731</ArticleId><ArticleId IdType="pubmed">31896594</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J., Liu F., Qi H., Tu W., Ward M.P., Ren M., Zhao Z., Su Q., Huang J., Chen X., et al. Changing epidemiology of hand, foot, and mouth disease in China, 2013-2019: A population-based study. Lancet Reg. Health West. Pac. 2022;20:100370. doi: 10.1016/j.lanwpc.2021.100370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2021.100370</ArticleId><ArticleId IdType="pmc">PMC8743221</ArticleId><ArticleId IdType="pubmed">35036978</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T., Xie T., Song X., Shen D., Li H., Yue L., Jiang Q., Zhu F., Meng H., Long R., et al. Safety and immunogenicity of an experimental live combination vaccine against enterovirus 71 and coxsackievirus A16 in rhesus monkeys. Hum. Vaccines Immunother. 2020;16:1586–1594. doi: 10.1080/21645515.2019.1709353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1709353</ArticleId><ArticleId IdType="pmc">PMC7482759</ArticleId><ArticleId IdType="pubmed">32159429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S., Jiang L., Liang Z., Mao Q., Su W., Zhang H., Li X., Jin J., Xu L., Zhao D., et al. Evaluation of monovalent and bivalent vaccines against lethal enterovirus 71 and eoxsackievirus A16 infection in newborn mice. Hum. Vaccines Immunother. 2014;10:2885–2895. doi: 10.4161/hv.29823.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.29823</ArticleId><ArticleId IdType="pmc">PMC5443096</ArticleId><ArticleId IdType="pubmed">25483672</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Ku Z., Liu Q., Leng Q., Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine. 2014;32:2406–2412. doi: 10.1016/j.vaccine.2014.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.03.012</ArticleId><ArticleId IdType="pubmed">24657161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z., Liu Q., Ye X., Cai Y., Wang X., Shi J., Li D., Jin X., An W., Huang Z. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine. 2014;32:4296–4303. doi: 10.1016/j.vaccine.2014.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.06.025</ArticleId><ArticleId IdType="pubmed">24950363</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.F., Deng Y.Q., Yang H.Q., Zhao H., Jiang T., Yu X.D., Li S.H., Ye Q., Zhu S.Y., Wang H.J., et al. A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates. J. Virol. 2013;87:13694–13705. doi: 10.1128/JVI.00931-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00931-13</ArticleId><ArticleId IdType="pmc">PMC3838253</ArticleId><ArticleId IdType="pubmed">24109223</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C.Y., Butrapet S., Tsuchiya K.R., Bhamarapravati N., Gubler D.J., Kinney R.M. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J. Virol. 2003;77:11436–11447. doi: 10.1128/JVI.77.21.11436-11447.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.21.11436-11447.2003</ArticleId><ArticleId IdType="pmc">PMC229366</ArticleId><ArticleId IdType="pubmed">14557629</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., Lang J., Ocran S., Mitchell F., Parsons M., et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 2004;78:4761–4775. doi: 10.1128/JVI.78.9.4761-4775.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.9.4761-4775.2004</ArticleId><ArticleId IdType="pmc">PMC387722</ArticleId><ArticleId IdType="pubmed">15078958</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Peng W., Ren J., Hu Z., Xu J., Lou Z., Li X., Yin W., Shen X., Porta C., et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 2012;19:424–429. doi: 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Iizuka S., Yamashita T., Minagawa H., Mizuta K., Okamoto M., Nishimura H., Sanjoh K., Katsushima N., Itagaki T., et al. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J. Virol. 2012;86:5686–5696. doi: 10.1128/JVI.00020-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00020-12</ArticleId><ArticleId IdType="pmc">PMC3347270</ArticleId><ArticleId IdType="pubmed">22438546</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J., Huo C., Qin H., Hu J., Lei L., Pan Z. Chimeric enterovirus 71 virus-like particle displaying conserved coxsackievirus A16 epitopes elicits potent immune responses and protects mice against lethal EV71 and CA16 infection. Vaccine. 2021;39:4135–4143. doi: 10.1016/j.vaccine.2021.05.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.093</ArticleId><ArticleId IdType="pubmed">34116877</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., He D., Li Z., Zheng J., Yang L., Yu M., Yu H., Chen Y., Que Y., Shih J.W., et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics. 2014;4:498–513. doi: 10.7150/thno.7457.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.7457</ArticleId><ArticleId IdType="pmc">PMC3964443</ArticleId><ArticleId IdType="pubmed">24669278</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., He D., Yang L., Li Z., Ye X., Yu H., Zhao H., Li S., Yuan L., Qian H., et al. A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH Loop and VP2 EF loop of enterovirus 71. Sci. Rep. 2015;5:12973. doi: 10.1038/srep12973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12973</ArticleId><ArticleId IdType="pmc">PMC4525384</ArticleId><ArticleId IdType="pubmed">26243660</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromeier M., Nair S.K. Recombinant poliovirus for cancer immunotherapy. Annu. Rev. Med. 2018;69:289–299. doi: 10.1146/annurev-med-050715-104655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-050715-104655</ArticleId><ArticleId IdType="pmc">PMC6013836</ArticleId><ArticleId IdType="pubmed">29414253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosaheb M.M., Dobrikova E.Y., Brown M.C., Yang Y., Cable J., Okada H., Nair S.K., Bigner D.D., Ashley D.M., Gromeier M. Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nat. Commun. 2020;11:524. doi: 10.1038/s41467-019-13939-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13939-z</ArticleId><ArticleId IdType="pmc">PMC6985231</ArticleId><ArticleId IdType="pubmed">31988324</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>